Bacterin International Holdings Inc. (fka BIHI)

[sdy]

BONE will present at SEVEN; Noble Financial Capital Markets' May 16, 2011
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62809423

[sdy]

BONE - http://investorshub.advfn.com/boards/board.aspx?board_id=20604

[silver100]

Ticker is BONE now.

[silver100]

Down to as low as $4 today on heavy volume (relative).

S1 is still not out yet though? More downside to come?

[silver100]

Some action here today... could be a wild ride next few weeks.

[iancassel]

I think you're pretty close.. 3.50-4 would be my guess

[ciciagt]

In August you thought "i think you'll be able to buy this below 2.50 when some stock gets freed up later this year. No rush here."

With BIHI's steady climb and holding in the $8 range, how likely do you think it is that the price will go that low? I'm thinking $4, but all I'm doing is guessing. I'd put more faith in your guess!

[iancassel]

lol....my guess is in 2-3 weeks.

[ciciagt]

That S1 is taking a long time to be designated "effective". I've reviewed the BIHI presentation at the micro-cap conference a few times, and I want in this thing! Let's get some shares in to the marketplace... :)

[iancassel]

yeah, i think registration will go effective in mid/late january...i think you'll be able to snag some in the $3-4 range

[silver100]

Still think this will dip back down into the $3s? Been watching this one. It never trades. I guess that when shares become free trading even a little selling pressure can take it down quite a bit.

[iancassel]

Good conference call: Company projecting revenues 15-17m 2010, and 52-57m for 2011. Taking the midpoint for 2011 company would generate EBITDA 17m, and Net Income of 11.5m or 0.23 EPS fully diluted.

[iancassel]

This is my largest holding in regards to $$. S1 registration should go effective in next 45 days as well as Nasdaq listing, so the stock should come back down to earth at that time ($3-4ish) as shares get unlocked from those that participated in the $1.60 PIPE. If the company executes like they think it will be a double digit stock in 2011.

[ciciagt]

Oh, never mind.......I see they put out a PR on it this morning.

[ciciagt]

Ian, any insight why these three directors resigned recently? They already replaced two..........
http://ih.advfn.com/p.php?pid=nmona&article=44889040&symbol=BIHI

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

Resignation of Directors

Messrs. Ken Calligar, Daniel Frank and Gary Simon have resigned from their positions as members of the Board of Directors of Bacterin International Holdings, Inc. (the “Company”). Ken Calligar and Daniel Frank resigned on October 15, 2010 and Gary Simon resigned on October 19, 2010.

Appointment of Directors

Effective as of October 21, 2010, the remaining members of the Company’s Board of Directors elected Michael Lopach and Jon Wickwire to fill two of the vacancies on the Company’s Board.

Mr. Lopach is a certified public accountant with over 30 years of accounting experience. Mr. Lopach spent 27 years of his career with Galusha, Higgens, Galusha & Co., the largest privately held accounting firm in Montana and northern Idaho, where he served as president and CEO. In 1999, Mr. Lopach founded Lopach & Carparelli PC, an accounting firm that focuses on medical practitioners. Mr. Lopach received his MBA from the University of Notre Dame. Mr. Lopach will serve as chairman of the Board’s Audit Committee.

Mr. Wickwire is an attorney and founding shareholder of Wickwire Gavin, P.C., a national construction law firm which merged with Akerman Senterfitt, one of the top 100 law firms in the United States. Mr. Wickwire served as lead counsel on major infrastructure litigation and alternative dispute resolutions, both domestically and internationally, throughout his 35 year career, and was the founding fellow of the American College of Construction Lawyers. Mr. Wickwire also served as the founding chairman of the College of Scheduling, an organization dedicated to advancing the techniques, practice and profession of project scheduling, and has authored several books and articles on construction and public contract law, including Construction Management: Law and Practice and The Construction Subcontracting Manual: Practice Guide with Forms . Mr. Wickwire is a graduate of the University of Maryland and Georgetown University Law Center. Mr. Wickwire has been a shareholder of the Company for approximately 5 years and has participated is several rounds of financing. Mr. Wickwire will serve as chairman of the Corporate Governance and Nominating Committees.

[iancassel]

Bacterin International Holdings, Inc. to Launch Dermal Scaffold Product Line Called hMatrix

http://finance.yahoo.com/news/Bacterin-International-prnews-3297080812.html?x=0&.v=1

Pretty amazing stuff.

[iancassel]

Bacterin International (BIHI): A Takeout Target in 2011

http://iancassel.com/2010/09/07/bacterin-international-bihi-a-takeout-target-in-2011/

[iancassel]

Complications rise along with off-label use of BMP-2

http://iancassel.com/2010/09/02/complications-rise-along-with-off-label-use-of-bmp-2/

really good news for BIHI

Again still think the stock is expensive, should come back down after S1 is registered.

[iancassel]

give it time...i wouldn't buy it up here..i think you'll be able to buy this below 2.50 when some stock gets freed up later this year. No rush here.

[ciciagt]

Price has sure popped (on low volume) with this news. I was waiting to see price dip under $3 again to start a position. Today's PR seems to have thrown a wrench in that plan!

[iancassel]

Bacterin and RyMed Collaborate and Receive FDA Consent to Commercialize Antimicrobial Needleless Connector

BELGRADE, Mont., Aug. 10 /PRNewswire-FirstCall/ -- Bacterin International Holdings, Inc. ("Bacterin" or the "Company") (OTC Bulletin Board:BIHI.ob - News), a developer of antimicrobial coatings for medical applications and revolutionary bone graft material, today announced that the U.S. Food and Drug Administration (FDA) has cleared RyMed Technologies' InVision-Plus® CS™ needleless IV connector for commercialization.

In a joint development project between RyMed and Bacterin, the InVision-Plus CS is treated with Bacterin's patented antimicrobial technology. The InVision-Plus CS is the only needleless IV connector to offer the combined antibacterial protection of chlorhexidine and silver. The device is designed to reduce potentially deadly, catheter-related bloodstream infections.

Bacterin has received an initial order for the InVision-Plus CS with full production expected by the fourth quarter of 2010. Bacterin will receive a royalty on all devices treated for RyMed.

Commenting on the FDA clearance, Mr. Dana W. Ryan, RyMed's president and CEO, said, "Our companies have put in a tremendous effort over several years to develop the InVision-Plus CS connector, combining RyMed's InVision-Plus technology with Bacterin's chlorhexidine/silver ion engineering. This product has the potential to take over the market and give clinicians a clear choice to protect their patients worldwide."

RyMed's InVision-Plus and InVision-Plus CS are needleless IV connectors designed to address intraluminal thrombotic catheter occlusion and catheter-related bloodstream infections. This proprietary needleless connector design is combined with Bacterin's unique patent-pending antimicrobial septa treatment that is effective for the life of the connector against the following microorganisms: Acinetobacter baumannii, Methicillin-resistant Staphylococcus aureus, Staphylococcus aureus, Escherichia coli, Candida albicans, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus epidermidis.

According to the Institute of Medicine in Washington, DC, preventable adverse events in the U.S., including hospital-originated infections, are responsible for 44,000 - 98,000 deaths annually. Hospital-developed infections involve 5% - 15% of patients, and more than 85% of primary bacteremias (the presence of bacteria in the bloodstream) are catheter related.

Last week, the FDA stated it is requiring makers of most IV needleless connectors to examine and report potential risks associated with the devices. One of the companies not mentioned in the FDA notice was RyMed Technologies.

As of October 2008, Medicare and Medicaid do not reimburse hospitals for the treatment of catheter-related bloodstream infection, which are estimated to cost approximately $40,000 per incident to treat. Hospitals within 28 states are now required to report their infection rates, and this practice is expected to be applied nationwide.

Mr. Guy Cook, Bacterin's President & CEO, added, "The FDA is addressing a serious issue in the industry. It has been estimated that as many as 30,000 patients die annually from catheter-related infections. Our two companies have created and are now at the point of commercializing a solution to a deadly problem. In 2001, as a result of a revision in the Bloodborne Pathogen Standard, the use of needleless systems was adopted by most healthcare facilities. In 2009, the U.S. market for vascular access devices and accessories was valued over $3 billion, a 5.4% increase over 2008; however, antimicrobial needleless connectors, a new addition to the market, represented only 0.02% of all needleless connectors in 2009. Today, with FDA support and the reimbursement changes by Medicare and Medicaid, we anticipate a tremendous need for our products."

[iancassel]

I own quite a bit of stock in this name. They did $7.8 million in revenues in 2009 and think they can do $20 million in 2010. It's in a sweet spot with the older demographic needing more and more orthopedic surgeries.

Stock will be illiquid until shares get freed up from the PIPE I participated in at $1.60 (around year end 2010 most likely), so the stock can trade anywhere until then. Not saying its a buy at $3 here at this time..a good buy around $2.

Only information out there on the company so far is this 8k:
http://www.sec.gov/Archives/edgar/data/1453593/000114420410036960/v189893_8k.htm

Q2 will be out before August 15th..